Hooman Mirzakhani, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pre-Eclampsia | 13 | 2023 | 1231 | 3.960 |
Why?
|
Vitamin D | 26 | 2024 | 3303 | 2.960 |
Why?
|
Asthma | 25 | 2024 | 6234 | 2.740 |
Why?
|
Prenatal Exposure Delayed Effects | 7 | 2024 | 2518 | 1.640 |
Why?
|
Vitamin D Deficiency | 7 | 2024 | 1388 | 1.500 |
Why?
|
Respiratory Sounds | 8 | 2023 | 702 | 1.460 |
Why?
|
Electroconvulsive Therapy | 4 | 2016 | 500 | 1.320 |
Why?
|
Fetal Blood | 3 | 2024 | 1347 | 1.110 |
Why?
|
Pregnancy | 40 | 2024 | 29874 | 1.010 |
Why?
|
Dietary Supplements | 10 | 2024 | 3415 | 1.010 |
Why?
|
Maternal Exposure | 4 | 2024 | 1067 | 0.980 |
Why?
|
Vitamins | 11 | 2024 | 1635 | 0.890 |
Why?
|
Pregnancy Trimester, First | 5 | 2022 | 907 | 0.830 |
Why?
|
Premature Birth | 4 | 2022 | 1782 | 0.760 |
Why?
|
Neuromuscular Depolarizing Agents | 2 | 2016 | 43 | 0.640 |
Why?
|
Androstanols | 2 | 2016 | 45 | 0.640 |
Why?
|
Succinylcholine | 2 | 2016 | 66 | 0.640 |
Why?
|
Pregnancy Complications | 3 | 2023 | 2947 | 0.640 |
Why?
|
Pregnancy Trimester, Third | 2 | 2022 | 583 | 0.630 |
Why?
|
Neuromuscular Nondepolarizing Agents | 2 | 2016 | 143 | 0.600 |
Why?
|
Cholecalciferol | 2 | 2024 | 553 | 0.560 |
Why?
|
Placenta | 3 | 2020 | 1709 | 0.540 |
Why?
|
Diabetes, Gestational | 2 | 2023 | 1248 | 0.540 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2015 | 107 | 0.500 |
Why?
|
Eczema | 3 | 2022 | 246 | 0.470 |
Why?
|
DNA Methylation | 2 | 2024 | 4398 | 0.430 |
Why?
|
Disease Susceptibility | 2 | 2019 | 1787 | 0.410 |
Why?
|
Antibiotics, Antitubercular | 1 | 2013 | 99 | 0.410 |
Why?
|
NFATC Transcription Factors | 3 | 2020 | 389 | 0.410 |
Why?
|
Anesthesia, Intravenous | 1 | 2013 | 128 | 0.410 |
Why?
|
Pharyngeal Diseases | 1 | 2013 | 134 | 0.400 |
Why?
|
Respiratory Aspiration | 1 | 2013 | 89 | 0.400 |
Why?
|
Gestational Age | 5 | 2023 | 3577 | 0.390 |
Why?
|
Neuromuscular Blockade | 1 | 2013 | 146 | 0.380 |
Why?
|
Developmental Disabilities | 1 | 2020 | 1509 | 0.380 |
Why?
|
Pharmacogenetics | 1 | 2015 | 675 | 0.370 |
Why?
|
Rifampin | 1 | 2013 | 339 | 0.370 |
Why?
|
Epigenesis, Genetic | 1 | 2024 | 3802 | 0.370 |
Why?
|
Immunomodulation | 1 | 2015 | 549 | 0.360 |
Why?
|
Pharynx | 1 | 2013 | 432 | 0.360 |
Why?
|
Neuromuscular Blocking Agents | 1 | 2011 | 129 | 0.360 |
Why?
|
Infant, Premature | 1 | 2020 | 2107 | 0.360 |
Why?
|
Muscle Weakness | 1 | 2013 | 412 | 0.350 |
Why?
|
Interleukin-8 | 2 | 2023 | 695 | 0.340 |
Why?
|
Female | 46 | 2024 | 392644 | 0.340 |
Why?
|
Environmental Exposure | 1 | 2024 | 4486 | 0.330 |
Why?
|
Infant, Newborn | 10 | 2024 | 26198 | 0.320 |
Why?
|
Child, Preschool | 15 | 2024 | 42230 | 0.300 |
Why?
|
MicroRNAs | 1 | 2023 | 3816 | 0.290 |
Why?
|
Propofol | 1 | 2013 | 603 | 0.280 |
Why?
|
Hypotension | 1 | 2013 | 879 | 0.280 |
Why?
|
Humans | 55 | 2024 | 761504 | 0.260 |
Why?
|
Double-Blind Method | 5 | 2020 | 12341 | 0.260 |
Why?
|
Hypersensitivity | 1 | 2015 | 1171 | 0.250 |
Why?
|
Body Mass Index | 6 | 2024 | 12953 | 0.230 |
Why?
|
Antidepressive Agents | 1 | 2015 | 2897 | 0.220 |
Why?
|
C-Reactive Protein | 3 | 2023 | 3826 | 0.210 |
Why?
|
Tissue Distribution | 2 | 2024 | 2265 | 0.210 |
Why?
|
Anesthesiology | 1 | 2013 | 1117 | 0.200 |
Why?
|
Calcifediol | 1 | 2023 | 161 | 0.200 |
Why?
|
Respiration, Artificial | 1 | 2013 | 2628 | 0.200 |
Why?
|
Adult | 21 | 2022 | 221177 | 0.200 |
Why?
|
Lung | 4 | 2022 | 10000 | 0.200 |
Why?
|
Cotinine | 2 | 2022 | 206 | 0.190 |
Why?
|
Young Adult | 12 | 2022 | 59243 | 0.190 |
Why?
|
Child | 16 | 2024 | 80153 | 0.180 |
Why?
|
Smoking | 1 | 2017 | 9053 | 0.180 |
Why?
|
Hypersensitivity, Immediate | 1 | 2022 | 347 | 0.170 |
Why?
|
Pregnancy Trimesters | 1 | 2020 | 197 | 0.160 |
Why?
|
Male | 20 | 2024 | 360804 | 0.160 |
Why?
|
Chorioamnionitis | 1 | 2020 | 156 | 0.160 |
Why?
|
Cell-Derived Microparticles | 1 | 2020 | 161 | 0.160 |
Why?
|
Airway Resistance | 1 | 2020 | 406 | 0.160 |
Why?
|
Food Supply | 1 | 2024 | 544 | 0.160 |
Why?
|
Epigenomics | 1 | 2024 | 943 | 0.160 |
Why?
|
Carbamazepine | 1 | 2019 | 224 | 0.150 |
Why?
|
Depression, Postpartum | 1 | 2022 | 346 | 0.150 |
Why?
|
Pregnancy Trimester, Second | 1 | 2020 | 731 | 0.150 |
Why?
|
Problem Solving | 1 | 2020 | 441 | 0.150 |
Why?
|
Maternal Age | 1 | 2020 | 809 | 0.140 |
Why?
|
Case-Control Studies | 7 | 2020 | 22176 | 0.130 |
Why?
|
Chemokines | 1 | 2020 | 960 | 0.130 |
Why?
|
Placebo Effect | 1 | 2020 | 518 | 0.130 |
Why?
|
Interleukin-9 | 1 | 2016 | 62 | 0.130 |
Why?
|
Fentanyl | 1 | 2019 | 434 | 0.130 |
Why?
|
Fish Oils | 1 | 2019 | 483 | 0.130 |
Why?
|
Mental Disorders | 1 | 2015 | 6845 | 0.120 |
Why?
|
Incidence | 5 | 2020 | 21353 | 0.120 |
Why?
|
Prospective Studies | 5 | 2022 | 54425 | 0.120 |
Why?
|
Genetic Predisposition to Disease | 4 | 2021 | 17904 | 0.120 |
Why?
|
Data Collection | 1 | 2023 | 3322 | 0.110 |
Why?
|
Drug Interactions | 2 | 2019 | 1416 | 0.110 |
Why?
|
Risk Factors | 6 | 2022 | 74206 | 0.110 |
Why?
|
Single-Blind Method | 1 | 2016 | 1572 | 0.100 |
Why?
|
Gene Regulatory Networks | 2 | 2018 | 1745 | 0.100 |
Why?
|
Pneumonia | 1 | 2024 | 2143 | 0.100 |
Why?
|
Prenatal Care | 1 | 2020 | 1139 | 0.100 |
Why?
|
Infant | 5 | 2024 | 36192 | 0.100 |
Why?
|
Vecuronium Bromide | 1 | 2011 | 33 | 0.100 |
Why?
|
gamma-Cyclodextrins | 1 | 2011 | 17 | 0.100 |
Why?
|
Atracurium | 1 | 2011 | 51 | 0.100 |
Why?
|
Convulsants | 1 | 2011 | 70 | 0.100 |
Why?
|
Food Hypersensitivity | 1 | 2019 | 729 | 0.100 |
Why?
|
Muscle Contraction | 1 | 2016 | 1201 | 0.100 |
Why?
|
Paralysis | 1 | 2013 | 250 | 0.090 |
Why?
|
Odds Ratio | 2 | 2020 | 9646 | 0.090 |
Why?
|
Medical Records | 1 | 2016 | 1408 | 0.090 |
Why?
|
International Classification of Diseases | 1 | 2016 | 909 | 0.090 |
Why?
|
Depressive Disorder | 2 | 2015 | 3728 | 0.090 |
Why?
|
Metabolome | 1 | 2017 | 989 | 0.090 |
Why?
|
Cross-Over Studies | 1 | 2016 | 2078 | 0.090 |
Why?
|
Isoquinolines | 1 | 2011 | 352 | 0.090 |
Why?
|
Magnesium | 1 | 2013 | 804 | 0.080 |
Why?
|
Delivery, Obstetric | 1 | 2016 | 940 | 0.080 |
Why?
|
Cohort Studies | 3 | 2020 | 41487 | 0.080 |
Why?
|
Anticonvulsants | 1 | 2019 | 1906 | 0.080 |
Why?
|
RNA, Messenger | 1 | 2023 | 12795 | 0.080 |
Why?
|
Cytokines | 1 | 2023 | 7396 | 0.080 |
Why?
|
Risk | 1 | 2020 | 9610 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6484 | 0.080 |
Why?
|
Aspirin | 1 | 2020 | 3133 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10766 | 0.070 |
Why?
|
Muscles | 1 | 2013 | 1576 | 0.070 |
Why?
|
Recurrence | 1 | 2020 | 8465 | 0.070 |
Why?
|
Linear Models | 1 | 2017 | 5871 | 0.070 |
Why?
|
Immunity, Innate | 1 | 2019 | 3065 | 0.070 |
Why?
|
Family | 1 | 2017 | 3194 | 0.070 |
Why?
|
Carrier Proteins | 1 | 2019 | 4936 | 0.070 |
Why?
|
Vascular Diseases | 1 | 2014 | 1161 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2021 | 15936 | 0.060 |
Why?
|
Communication | 1 | 2019 | 3873 | 0.060 |
Why?
|
Phenotype | 3 | 2020 | 16591 | 0.060 |
Why?
|
DNA | 1 | 2018 | 7212 | 0.060 |
Why?
|
Organ Transplantation | 1 | 2014 | 1157 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9420 | 0.060 |
Why?
|
Monitoring, Physiologic | 1 | 2011 | 1779 | 0.060 |
Why?
|
Patient Discharge | 1 | 2016 | 3443 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 2 | 2020 | 1844 | 0.050 |
Why?
|
Aged | 5 | 2019 | 169289 | 0.050 |
Why?
|
Liver Transplantation | 1 | 2014 | 2330 | 0.050 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3808 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2016 | 7594 | 0.050 |
Why?
|
Blood Pressure | 1 | 2018 | 8481 | 0.050 |
Why?
|
Genome-Wide Association Study | 2 | 2020 | 12690 | 0.050 |
Why?
|
Mass Spectrometry | 2 | 2020 | 2192 | 0.050 |
Why?
|
Europe | 2 | 2020 | 3422 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12059 | 0.050 |
Why?
|
Adolescent | 3 | 2024 | 88319 | 0.050 |
Why?
|
Age Factors | 1 | 2019 | 18395 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10209 | 0.050 |
Why?
|
Middle Aged | 5 | 2019 | 220895 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4174 | 0.050 |
Why?
|
Logistic Models | 1 | 2015 | 13255 | 0.050 |
Why?
|
Aged, 80 and over | 2 | 2016 | 58976 | 0.050 |
Why?
|
Critical Illness | 1 | 2013 | 2723 | 0.040 |
Why?
|
Vitamin D-Binding Protein | 1 | 2021 | 131 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2013 | 3745 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2016 | 64680 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2017 | 15842 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 413 | 0.040 |
Why?
|
Th2 Cells | 1 | 2024 | 1060 | 0.040 |
Why?
|
Seizures | 1 | 2011 | 2957 | 0.040 |
Why?
|
Receptors, Calcitriol | 1 | 2021 | 360 | 0.040 |
Why?
|
Prognosis | 1 | 2019 | 29625 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 11903 | 0.040 |
Why?
|
Half-Life | 1 | 2019 | 651 | 0.040 |
Why?
|
Respiratory Hypersensitivity | 1 | 2019 | 273 | 0.040 |
Why?
|
Mucus | 1 | 2019 | 341 | 0.040 |
Why?
|
Prevalence | 1 | 2015 | 15732 | 0.040 |
Why?
|
Muscle, Skeletal | 1 | 2013 | 4948 | 0.040 |
Why?
|
Inflammation | 3 | 2024 | 10773 | 0.040 |
Why?
|
Tryptophan | 1 | 2019 | 482 | 0.040 |
Why?
|
Animals | 3 | 2024 | 168459 | 0.040 |
Why?
|
Interleukin-2 | 1 | 2024 | 1889 | 0.040 |
Why?
|
T-Box Domain Proteins | 1 | 2019 | 469 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15266 | 0.030 |
Why?
|
Risk Assessment | 1 | 2018 | 23995 | 0.030 |
Why?
|
Spirometry | 1 | 2020 | 929 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39106 | 0.030 |
Why?
|
Amines | 1 | 2017 | 281 | 0.030 |
Why?
|
Michigan | 1 | 2016 | 339 | 0.030 |
Why?
|
Eosinophils | 1 | 2020 | 950 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2019 | 983 | 0.030 |
Why?
|
Genotype | 2 | 2021 | 12990 | 0.030 |
Why?
|
Educational Status | 1 | 2022 | 2522 | 0.030 |
Why?
|
Area Under Curve | 1 | 2019 | 1638 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2024 | 2093 | 0.030 |
Why?
|
Allergens | 1 | 2021 | 1432 | 0.030 |
Why?
|
United States | 4 | 2024 | 72334 | 0.030 |
Why?
|
Metabolic Networks and Pathways | 1 | 2017 | 789 | 0.030 |
Why?
|
Brain | 1 | 2020 | 27112 | 0.030 |
Why?
|
Poverty | 1 | 2024 | 2698 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2014 | 15631 | 0.030 |
Why?
|
Lymphocytes | 1 | 2019 | 2612 | 0.020 |
Why?
|
Morbidity | 1 | 2016 | 1750 | 0.020 |
Why?
|
Time Factors | 1 | 2013 | 39967 | 0.020 |
Why?
|
Fetal Development | 1 | 2016 | 769 | 0.020 |
Why?
|
Trans-Activators | 1 | 2020 | 2856 | 0.020 |
Why?
|
Veins | 1 | 2014 | 768 | 0.020 |
Why?
|
Arteries | 1 | 2014 | 1123 | 0.020 |
Why?
|
Fatty Acids | 1 | 2017 | 1808 | 0.020 |
Why?
|
Steroids | 1 | 2014 | 929 | 0.020 |
Why?
|
Immune System | 1 | 2014 | 796 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2017 | 1886 | 0.020 |
Why?
|
History, 21st Century | 1 | 2014 | 1567 | 0.020 |
Why?
|
Metabolomics | 1 | 2017 | 1659 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2023 | 8002 | 0.020 |
Why?
|
Proteomics | 1 | 2020 | 3849 | 0.020 |
Why?
|
History, 20th Century | 1 | 2014 | 2767 | 0.020 |
Why?
|
Proteins | 1 | 2020 | 6032 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2014 | 2303 | 0.020 |
Why?
|
Mice | 2 | 2024 | 81525 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2013 | 80636 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2019 | 14414 | 0.010 |
Why?
|
Massachusetts | 1 | 2016 | 8830 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10194 | 0.010 |
Why?
|
Depression | 1 | 2022 | 8124 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 2014 | 3396 | 0.010 |
Why?
|
Graft Rejection | 1 | 2014 | 4445 | 0.010 |
Why?
|
Hypertension | 1 | 2020 | 8540 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18252 | 0.010 |
Why?
|
Pediatrics | 1 | 2014 | 3589 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 20098 | 0.010 |
Why?
|
Apoptosis | 1 | 2014 | 9486 | 0.010 |
Why?
|